InflaRx N.V. (NASDAQ:IFRX) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.43.

Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Monday, September 21st. Needham & Company LLC began coverage on shares of InflaRx in a report on Monday, September 14th. They issued a “buy” rating and a $8.00 price objective for the company. Zacks Research cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 25th. Finally, Cantor Fitzgerald upped their price objective on shares of InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

Hedge Funds Weigh In On InflaRx

Institutional investors and hedge funds have recently modified their holdings of the business. SteelPeak Wealth LLC purchased a new position in InflaRx during the third quarter worth approximately $419,000. AXQ Capital LP purchased a new stake in shares of InflaRx in the second quarter valued at approximately $41,000. Montanova Capital LLC increased its position in shares of InflaRx by 189.1% in the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock valued at $51,372,000 after buying an additional 15,000,000 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of InflaRx in the second quarter valued at approximately $1,737,000. Finally, ADAR1 Capital Management LLC acquired a new stake in InflaRx in the 2nd quarter valued at $6,720,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Stock Up 9.8%

InflaRx stock opened at $1.45 on Tuesday. InflaRx has a 52 week low of $0.80 and a 52 week high of $2.95. The business’s 50-day moving average price is $1.95 and its 200 day moving average price is $1.91.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Sell-side analysts forecast that InflaRx will post -0.31 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for severe and life-threatening inflammatory diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune system that can contribute to tissue damage when excessively activated.

InflaRx’s lead product is vilobelimab, a monoclonal antibody designed to selectively block the complement protein C5a while preserving other components of the immune response.